.svg)
Venture Medical Announces Acquisition of Select ProgenaCare Global Assets to Expand Advanced Wound Care Portfolio
Venture Medical, LLC, a leader in wound care solutions, today announced its acquisition of certain assets of ProgenaCare Global, LLC, a biotechnology company known for its innovative, keratin-based wound healing technologies, including ProgenaMatrix®, along with intellectual property supporting an expected future product line. Howard Walthall, former CEO of ProgenaCare, has also joined Venture Medical as Senior Vice President of Product Development.
Venture Medical, LLC, a leader in wound care solutions, today announced its acquisition of certain assets of ProgenaCare Global, LLC, a biotechnology company known for its innovative, keratin-based wound healing technologies, including ProgenaMatrix®, along with intellectual property supporting an expected future product line. Howard Walthall, former CEO of ProgenaCare, has also joined Venture Medical as Senior Vice President of Product Development.
This acquisition marks a significant milestone in Venture Medical’s mission to deliver clinically proven, accessible, and ethically grounded wound care solutions to providers across the country. By integrating ProgenaCare’sproprietary keratin platform, Venture Medical strengthens its advanced therapy portfolio with regenerative technologies that support healing and help improve outcomes for patients with chronic and hard-to-heal wounds.
“Venture Medical is at the forefront of patient-centered innovation. Between their comprehensive product formulary and proprietary Venture OneView platform, they are positioned to become a nationwide leader in the wound care space,” said Bert Jones, Chairman of the Board of ProgenaCare Global. “We are excited to see our mission continue with a company that shares our values and has the infrastructure to scale our impact.”
“ProgenaCare has long stood for integrity, science, and healing — all values that align seamlessly with Venture Medical,” said John Schroeder, CEO of Venture Medical. “With Howard Walthall on board and these technologies in our portfolio, we’re positioned to elevate the standard of care and improve patient outcomes in ways that are both clinically meaningful and beneficial to the industry as a whole.”
The acquisition includes full rights to ProgenaMatrix®, the first and only keratin matrix cleared by the FDA for wound management, and contractual rights to distribute revyve™, an advanced antimicrobial hydrogel. Both products are now available through Venture Medical’s extensive distribution network.
Click here to view the official press release.
About Venture Medical, LLC:
Venture Medical is a groundbreaking healthcare services company with a decade-long history of innovation, dedication, and consistent growth in the field of wound care and healing. Over the past 15 years, Venture Medical has expanded its reach across the United States and has grown to become a leading commercial partner and software services provider for manufacturers and end users of biologics, advanced diagnostics, durable medical equipment, and capital goods.
About ProgenaCare Global, LLC:
ProgenaCare Global is a biotechnology company focused on developing keratin-based regenerative therapies. Its core technologies are designed to accelerate tissue regeneration, reduce inflammation, and promote healthy wound closure with biocompatible and biologically active materials.
Venture Medical Announces Strategic Partnership with Plasmacure to Bring Groundbreaking Cold Plasma Therapy for Chronic Wounds to the U.S. Market
Venture Medical, LLC, a leading provider of advanced wound care solutions, is proud to announce a strategic development and distribution agreement in principle with Plasmacure B.V., the Netherlands-basedMedTech innovator behind the revolutionary PLASOMA cold plasma system for chronic wound treatment.
.png)
Open Wound Research and Venture Medical Announce Collaboration to Advance Pressure Ulcer Research
Open Wound Research and Venture Medical, LLC have entered into a collaborative research agreement to advance the study of pressure ulcer treatment. As part of this partnership, Venture Medical has acquired extensive pressure ulcer data from Open Wound Research to evaluate the efficacy of CAMPS in comparison to standard of care (SOC) treatments.
John Schroeder and Jason Matuszewski Give Presentation At CAMPS 2025
Last week at CAMPS 2025, John Schroeder, CEO of Venture Medical, and Jason Matuszewski, CEO of BioStem Technology, took the stage to deliver a compelling presentation titled “Why You Should Care About Investors in the Wound Care Space.”
.png)
Venture Medical Launches New Website!
We invite you to explore our brand new website
